CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agonist (TICA™), and an EphA2/CD137 TICA will be presented during an […]
Therapeutics
Zacks Investment Research Upgrades Bicycle Therapeutics (NASDAQ:BCYC) to Hold
Zacks Investment Research upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, “Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are […]
Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Upgraded by BidaskClub
Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports. A number of other equities research analysts have also recently weighed in on BCYC. Cantor Fitzgerald started coverage on Bicycle Therapeutics in a research note […]
Analysts Set Bicycle Therapeutics Limited (NASDAQ:BCYC) PT at $24.80
Bicycle Therapeutics Limited (NASDAQ:BCYC) has been given a consensus recommendation of “Buy” by the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. […]
Bicycle Therapeutics Announces Expansion of Scientific Advisory Board
– Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that leaders in the fields of oncology, […]
Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has completed its at-the-market (ATM) offering program initiated during the third quarter, generating gross proceeds of $50.0 million. […]
Bicycle Therapeutics Sees Hammer Chart Pattern: Time to Buy? – April 8, 2020
Bicycle Therapeutics plc (BCYC – Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because BCYC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. What is a Hammer Chart Pattern? A hammer chart […]
Bicycle Therapeutics Announces Pipeline Progress Update
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced progress updates across its wholly-owned and partnered programs in oncology and non-oncology indications. “We and our partners have recently achieved […]
Bicycle Therapeutics partners with Roche
Bicycle Therapeutics, a Cambridge, UK-based biotech, developing proprietary bicyclic peptides has attracted the attention of Roche subsidiary, Genentech. The two companies agreed a collaboration agreement, with Bicycle receiving $30m (€27.4m) in an upfront fee and eligible for a further $1.7bn (€1.55bn) dependent upon milestones met. The focus will be on […]